Silexion Faces Potential Nasdaq Delisting Amid Promising Preclinical Results

Company Introduction

Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven solid tumors. Incorporated in the Cayman Islands and headquartered in Israel, the company’s lead candidate, SIL-204, is derived from its first-generation siG12D-LODER™ platform. As of July 31, 2025, SLXN shares closed at USD 15.00, reflecting a 32.51% increase on a volume of 974,945 shares on the NASDAQ exchange.

Corporate Structure

Silexion employs between 11 and 50 people across research, clinical development, manufacturing, and corporate functions. Ilan Hadar serves as Chairman and Chief Executive Officer, Mirit Horenshtein Hadar as Chief Financial Officer, and Mitchell Shirvan, Ph.D., as Chief Scientific Officer. The company partners with LGC Axolabs (siRNA manufacturing, Petaluma, CA), Evonik Corporation (extended-release formulation, Birmingham, AL), and Catalent (advanced siRNA formulation development and clinical manufacturing).

RNA interference by Pawel Czerwinski

Recent Developments

On May 22, 2025, Silexion received a notice from the Nasdaq Listing Qualifications Department indicating potential delisting due to failure to meet minimum market value thresholds before the end of its 180-day compliance period (which ended on May 19, 2025). The company intends to appeal this decision and is evaluating a transfer to the Nasdaq Capital Market.

On May 29, 2025, Silexion announced preclinical results for SIL-204 demonstrating dose-dependent inhibition of KRAS G12D mutant cell lines in pancreatic (Panc-1), colorectal (GP2D), and lung (A427) models. In GP2D cells, SIL-204 achieved approximately 90% inhibition of proliferation at nanomolar concentrations. A follow-up study on A427 lung cancer cells is planned in the coming weeks.

The company has scheduled an Extraordinary General Meeting of shareholders for August 12, 2025, to seek approval to increase its authorized share capital.

Financial and Strategic Analysis

According to its definitive proxy statement filed on July 31, 2025 (DEF 14A), Silexion proposes to raise its authorized share capital from USD 20,000 (1,481,482 ordinary shares) to USD 121,500 (9,000,000 ordinary shares). Following a 1-for-15 reverse stock split, only 529,302 authorized but unissued shares remain, which could limit flexibility for future financing. To comply with Nasdaq Capital Market equity standards, Silexion must reach at least USD 2.5 million in shareholders’ equity by September 19, 2025.

TipRanks data report a consensus analyst rating of “Buy” with a USD 9.00 price target. However, TipRanks’ AI Analyst (“Spark”) categorizes SLXN as “Underperform.” The stock's market capitalization is approximately USD 8.57 million, with zero reported revenues and negative equity indicating considerable financial risks.

Market Position and Industry Context

KRAS mutations significantly contribute to solid tumors—occurring in about 90% of pancreatic cancers, 45% of colorectal cancers, and 35% of non-squamous non-small-cell lung cancers—collectively valued at over USD 30 billion annually. Conventional small-molecule and antibody treatments have faced challenges in targeting many KRAS variants, highlighting a potential opportunity for RNAi-based approaches. Silexion’s focus on locally administered, extended-release siRNA situates it among a select group of companies advancing gene-silencing modalities in oncology.

tl;dr

— On May 22, 2025, Silexion received notice of potential delisting from Nasdaq and plans to appeal or transfer to the Nasdaq Capital Market.
— On May 29, 2025, preclinical data for SIL-204 showed up to 90% inhibition of KRAS G12D mutant cancer cell lines; further lung cell studies are underway.
— An Extraordinary General Meeting is set for August 12, 2025, to approve an increase in authorized share capital.
— The company must achieve USD 2.5 million in shareholders’ equity by September 19, 2025, to maintain Nasdaq compliance.